CT Healthcare Trust plc (LSE:CTHT) has spent 2026 reshaping itself. A new manager, a new name and a regular tender mechanism have changed how the healthcare Investment trust returns capital, and the completion of its latest quarterly tender on 16 September 2026 offers a useful point to examine how that framework is working in practice.

A healthcare trust under new management

The company invests in global healthcare stocks. It was previously known as Bellevue Healthcare Trust plc, and according to its change-of-name announcement of 24 March 2026, it adopted the CT Healthcare Trust name with effect from 19 March and began trading on the Main Market of the London Stock Exchange under the new ticker CTHT from 25 March 2026. Its ISIN was unchanged.

The rebrand followed a general meeting held on 4 March 2026, at which shareholders approved every resolution put to them. These included the appointment of Columbia Threadneedle as alternative investment Fund Manager and investment manager with effect from 5 March, a change to the investment objective, and the removal of the former Redemption Facility from the articles. The company described its new approach as an "established healthcare strategy" built on "active management through the identification of potential winners and laggards", pointing to ageing populations, chronic disease and innovation in areas such as gene therapy and digital health as long-term drivers.

From a large exit to quarterly tenders

The transition came with a substantial return of capital. The March tender offer saw 29,922,562 shares tendered, about 40.9% of the 73,199,234 shares then in issue, at a purchase price of 139.7186 pence per share. The company also said a Columbia Threadneedle affiliate intended to subscribe for approximately US$25 million of new shares after completion to support scale and liquidity.

Since then, the board has followed through on a commitment made to shareholders in February 2026 to offer regular exits. The first quarterly tender, announced on 14 May 2026, allowed shareholders to tender up to 15% of the issued share Capital at net asset value per share less tender costs, with those costs capped.

The September tender and latest NAV

On 16 September 2026, the trust announced completion of the quarterly tender launched on 6 August, under which 3,885,283 ordinary shares were bought back. Following the transaction, the company reported 42,371,648 shares in issue and 272,780,661 held in treasury. Payment to tendering shareholders was due within ten Business days.

Its most recent weekly valuation, published on 23 September 2026, put net asset value at 134.58p per share as at 22 September, compared with 136.27p on 15 September. The company has also announced near-daily transactions in its own shares throughout September, indicating Buybacks alongside the tender programme.

What the numbers suggest

The size of the September tender, relative to the 15% maximum available, suggests that the appetite to exit has eased considerably since the March offer, when a large proportion of the register chose to leave. However, the share count is now far smaller than before the manager change, and a smaller trust can face higher relative running costs and thinner trading in its shares.

Risks and points to watch

Healthcare stocks remain exposed to drug-pricing policy, clinical trial outcomes, regulatory decisions and currency movements, all of which can move NAV. Repeated tenders shrink the capital base, and future Demand to exit is uncertain. Investors may also watch whether the manager's longer-term record under the new mandate supports the case for the trust at its reduced scale, and whether new share issuance materialises.

Conclusion

CT Healthcare Trust is using quarterly tenders at close to net asset value as a core part of its post-transition structure. The September tender completed with far lower take-up than the March exit, leaving a smaller, Columbia Threadneedle-managed trust whose next test is performance and scale.